Armata Pharmaceuticals
ARMP
36 hedge funds and large institutions have $7.85M invested in Armata Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 11 increasing their positions, 1 reducing their positions, and 4 closing their positions.
27,151% more capital inflows, than outflows
Capital inflows: $2.69M | Capital outflows: $9.9K
1,000% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 1
200% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 4
29% more funds holding
Funds holding: 28 → 36 (+8)
1.33% more ownership
Funds ownership: 2.1% → 3.43% (+1.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$766K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$332K |
| 3 |
BlackRock
New York
|
+$253K |
| 4 |
Goldman Sachs
New York
|
+$248K |
| 5 |
OMERS Administration Corp
Toronto,
Ontario, Canada
|
+$154K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Group One Trading
Chicago,
Illinois
|
-$8.94K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
-$548 |
| 3 |
Salem Investment Counselors
Winston Salem,
North Carolina
|
-$298 |
| 4 |
JP Morgan Chase
New York
|
-$72 |
| 5 |
Barclays
London,
United Kingdom
|
-$18 |
ARMP Hedge Fund Activity: Q4 2025 in Review
36 of the 8,297 institutional investors tracked by Wall St. Rank reported a position in Armata Pharmaceuticals (ARMP) for Q4 2025, worth a combined $7.85M — up 245% from $2.27M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ARMP positions and 4 closed out — a net gain of 8 holders — while 11 added to existing stakes and 1 trimmed.
The largest buyer was 683 Capital Management, opening a new position worth an estimated $766K. The largest seller was Group One Trading, exiting entirely with an estimated $8.94K sold.
- 36 institutional investors held Armata Pharmaceuticals (ARMP) as of Q4 2025, up from 28 in Q3 2025.
- Funds reported $7.85M of Armata Pharmaceuticals stock for Q4 2025, up 245% quarter-over-quarter.
- 12 funds opened new Armata Pharmaceuticals positions in Q4 2025 and 4 closed out, a net change of +8 holders.
- The largest Armata Pharmaceuticals buyer in Q4 2025 was 683 Capital Management, an estimated $766K added.
- The largest Armata Pharmaceuticals seller in Q4 2025 was Group One Trading, an estimated $8.94K sold.
Based on aggregated 13F filings for Q4 2025.